Plain-English translation of NCT04703101 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment approach for people with locally advanced rectal cancer (stages II–III). You would receive a 5-day course of focused radiation therapy, followed by chemotherapy with either mFOLFOX6 or CapeOX. The goal is to shrink the cancer enough that some patients may avoid surgery altogether, or have a smaller operation.
Currently, most people with advanced rectal cancer need surgery to remove part or all of the rectum, which can affect bowel function and quality of life. This trial is exploring whether the new treatment approach can achieve complete tumor shrinkage without surgery, helping patients preserve normal bowel function.
You likely qualify if…
You likely don't qualify if…
You would start with 5 consecutive days of radiation therapy to your rectal area. After a short break of 1–2 weeks, you would begin chemotherapy, receiving either intravenous drugs every 2 weeks for up to 8 cycles, or oral medication every 3 weeks for up to 6 cycles. About 8–12 weeks after finishing all treatment, your doctors would check whether the cancer has completely disappeared using imaging and scans. If the cancer is completely gone, you would proceed with close monitoring instead of surgery. If some tumor remains, you would have surgery to remove it.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
United States